12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Medivation, Astellas sales and marketing update

Medivation and partner Astellas launched Xtandi enzalutamide in the U.S. to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. The wholesale...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >